Human platelet lysate

from Wikipedia, the free encyclopedia

Human platelet lysate ( HPL ) is obtained from platelet-rich blood plasma and is a main component of many nutrient media that are required for the rearing and cultivation of human cells in cell culture .

Areas of application

The use of HPL for the expansion of mesenchymal stem cells was first proposed by Doucet et al. described. Since then, HPL has proven to be an effective cell culture additive that is now used in many research laboratories as well as under clinical conditions. HPL is an alternative and can represent a complete replacement for fetal calf serum (FCS), which has been criticized for its animal origin and its ethically questionable extraction.

HPL can be used for the isolation of a large number of different cell types, including human endothelial cells , human fibroblasts and mesenchymal stem cells from various tissue types.

Manufacture and use

HPL is obtained from platelet-rich blood plasma. The manufacturing process is quite simple with multiple freezing and thawing steps as well as subsequent centrifugation and filtration. In order to inhibit coagulation, heparin must be added to some HPLs before the HPL is added to the culture medium. Defibrinogenized HPLs are also available, which can be used to inhibit coagulation without adding heparin

HPL is usually used in a concentration of 10 percent. Protocols have been developed to generate large pools of HPL in order to compensate for the dispenser-related fluctuations in the composition from batch to batch. Alternatively, it is possible to use autologous HPL to minimize the risk of immunological reactions or infections .

In addition to processing for research purposes, HPL can be produced for clinical use in accordance with the so-called Good Manufacturing Practice (GMP).

history

In 2005, Doucet et al. a study investigating the extent to which HPL can replace the FCS for the in vitro production of mesenchymal stem cells. But it was not until 2010 that the US company Mill Creek Life Sciences brought the first HPL for the cultivation of mesenchymal stem cells in clinical use onto the market.

providers

In addition to the pioneer Mill Creek Life Sciences, there are now other providers in the USA. In Europe, HPL is offered by PL BioScience and Trinova Biochem GmbH (CRUX RUFA Media Supplements). The companies sometimes offer the HPL in different qualities: as a product for pure research purposes as well as in accordance with GMP.

swell

Individual evidence

  1. Sandra Laner-Plamberger, Thomas Lener, Doris Schmid, Doris A. Streif, Tina Salzer: Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate . In: Journal of Translational Medicine . tape 13 , no. 1 , December 2015, ISSN  1479-5876 , p. 354 , doi : 10.1186 / s12967-015-0717-4 ( biomedcentral.com [accessed December 15, 2017]).
  2. Christelle Doucet et al: Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications . In: Journal of Cellular Physiology . tape 205 , no. 2 , November 2005, p. 228-236 , doi : 10.1002 / jcp.20391 , PMID 15887229 .